Reviewer's report

Title: Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

Version: 3 Date: 4 March 2014

Reviewer: Bjorn Meijers

Reviewer's report:

- Major Compulsory Revisions
  None

- Minor Essential Revisions
  * I would suggest adding the table included in the rebuttal to the final manuscript (see table summarizing available studies concerning the effect of phosphate binder therapy on FGF23)

  * Determination of urine volumes is not an appropriate manner evaluating completeness of 24h urinary collections. If the authors didn't determine urinary excretion of creatinine, this should be added as a limitation of the current study.

- Discretionary Revisions
  None

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests